As of 2025-07-01, the Relative Valuation of VistaGen Therapeutics Inc (VTGN) is (33.19) USD. This relative valuation is based on P/E multiples. With the latest stock price at 1.97 USD, the upside of VistaGen Therapeutics Inc based on Relative Valuation is -1784.9%.
The range of the Relative Valuation is (27.01) - (37.01) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 15.0x - 22.6x | 18.8x |
| Forward P/E multiples | 16.5x - 26.9x | 21.7x |
| Fair Price | (27.01) - (37.01) | (33.19) |
| Upside | -1471.2% - -1978.7% | -1784.9% |
| Date | P/E |
| 2025-06-27 | -1.20 |
| 2025-06-26 | -1.25 |
| 2025-06-25 | -1.24 |
| 2025-06-24 | -1.28 |
| 2025-06-23 | -1.20 |
| 2025-06-20 | -1.22 |
| 2025-06-18 | -1.26 |
| 2025-06-17 | -1.45 |
| 2025-06-16 | -1.44 |
| 2025-06-13 | -1.35 |
| 2025-06-12 | -1.41 |
| 2025-06-11 | -1.44 |
| 2025-06-10 | -1.46 |
| 2025-06-09 | -1.43 |
| 2025-06-06 | -1.44 |
| 2025-06-05 | -1.45 |
| 2025-06-04 | -1.46 |
| 2025-06-03 | -1.46 |
| 2025-06-02 | -1.48 |
| 2025-05-30 | -1.57 |
| 2025-05-29 | -1.56 |
| 2025-05-28 | -1.54 |
| 2025-05-27 | -1.48 |
| 2025-05-23 | -1.47 |
| 2025-05-22 | -1.48 |
| 2025-05-21 | -1.48 |
| 2025-05-20 | -1.60 |
| 2025-05-19 | -1.55 |
| 2025-05-16 | -1.50 |
| 2025-05-15 | -1.40 |
| 2025-05-14 | -1.38 |
| 2025-05-13 | -1.45 |
| 2025-05-12 | -1.42 |
| 2025-05-09 | -1.37 |
| 2025-05-08 | -1.37 |
| 2025-05-07 | -1.32 |
| 2025-05-06 | -1.31 |
| 2025-05-05 | -1.43 |
| 2025-05-02 | -1.45 |
| 2025-05-01 | -1.44 |
| 2025-04-30 | -1.43 |
| 2025-04-29 | -1.40 |
| 2025-04-28 | -1.40 |
| 2025-04-25 | -1.35 |
| 2025-04-24 | -1.43 |
| 2025-04-23 | -1.33 |
| 2025-04-22 | -1.25 |
| 2025-04-21 | -1.28 |
| 2025-04-17 | -1.29 |
| 2025-04-16 | -1.26 |